Phase 2 Evidence and Impact Analysis
All 37 articles classified. Scoring 37 articles across 5 dimensions with independent judgment applied to each. All articles are peer-reviewed (no preprint cap applies). Access is abstract-only throughout — scores reflect this limitation conservatively.
Article 1 — Orforglipron Phase 3 (ATTAIN-J) | PMID 42962687
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | First oral non-peptide GLP-1RA Phase 3 data in a Japanese-specific population; oral formulation is genuinely novel vs. injectable GLP-1s |
| Clinical Relevance | 8 | Phase 3 RCT; directly informs prescribing for obesity in Japan; oral route removes injection barrier |
| Population Reach | 8 | Obesity affects hundreds of millions globally; Japan-specific data fills a real evidence gap for Asian populations |
| Implementation Speed | 8 | Phase 3 complete; regulatory submission likely imminent; oral dosing accelerates uptake |
| Evidence Strength | 8 | Double-blind RCT; 72-week duration; well-powered for a Phase 3; abstract-only limits full assessment |
- Key quantitative result: Substantially more clinically meaningful weight loss vs. placebo across all doses at 72 weeks (exact % not available from abstract)
- External validation: Single trial; no independent replication yet
- Main limitation: Abstract-only; Japan-only population limits immediate global generalizability; no head-to-head vs. injectable GLP-1s
- Equity implications: Benefits Japanese patients underrepresented in prior GLP-1 trials; globally, oral route may improve access for injection-averse patients; cost barriers likely remain high
- Evidence Maturity (confirmed): Validated ✓
Article 2 — myESCAP cfDNA Methylation Assay for Esophageal Cancer | PMID 42962916
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | cfDNA methylation PCR + ML for esophageal cancer is novel in multicenter validated form; prior work was single-center |
| Clinical Relevance | 7 | Esophageal cancer has very poor prognosis; a non-invasive screening tool addresses real clinical gap, though early-stage sensitivity limitation is significant |
| Population Reach | 7 | Esophageal cancer is highly prevalent in East Asia and parts of Africa; global burden ~600K deaths/year |
| Implementation Speed | 5 | Retrospective case-control design; prospective screening trials needed before clinical adoption |
| Evidence Strength | 7 | Multicenter validation (n=1,044); AUC ~0.82; independent validation cohort present; retrospective design and abstract-only are limiting |
- Key quantitative result: AUC ~0.82; sensitivity ~76%; specificity ~89%; stage I sensitivity limited (exact figure not in abstract)
- External validation: Multicenter design with independent validation cohort — genuine strength
- Main limitation: Retrospective case-control; early-stage sensitivity is acknowledged as insufficient; no prospective screening data
- Equity implications: High-burden populations in East Asia, sub-Saharan Africa would benefit most; these same regions have least access to endoscopic screening — blood-based test could be transformative if access economics allow
- Evidence Maturity (confirmed): Validated ✓ (for a diagnostic study; prospective validation still needed)
Article 3 — ML-Enhanced Terahertz-Colorimetric Metadevice for Pancreatic Cancer miRNA | PMID 42961485
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 9 | Dual-mode terahertz + colorimetric metadevice for multiplex miRNA is highly novel; no comparable platform in clinical pipeline |
| Clinical Relevance | 4 | Pancreatic cancer detection need is enormous, but n=75 is far too small and platform is extremely early-stage; clinical relevance is potential, not current |
| Population Reach | 7 | Pancreatic cancer kills ~500K/year globally with very poor early detection rates; unmet need is severe |
| Implementation Speed | 2 | Specialized metadevice hardware; proof-of-concept only; years from clinical use |
| Evidence Strength | 3 | n=75; small training/validation split; single institution implied; no independent external validation; "96% accuracy" in this context is likely overfitted |
- Key quantitative result: >96% diagnostic accuracy in both cohorts; 100% sensitivity for early-stage pancreatic cancer in small cohort
- External validation: None external; internal validation only
- Main limitation: Tiny sample; likely significant overfitting; specialized hardware not deployable in most clinical settings; not peer-comparable to blood-based tests
- Equity implications: If commercialized, specialized hardware likely concentrated in well-resourced centers initially; pancreatic cancer disproportionately affects lower-income populations with less access to specialty care
- Evidence Maturity (revised): Exploratory ✓ (confirmed; caution warranted on accuracy claims)
Article 4 — CAR-T vs. Bispecific Antibody in Relapsed/Refractory Follicular Lymphoma | PMID 42962270
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | First substantial multicenter real-world head-to-head comparison of CAR-T vs. bispecific in r/r FL; adds "time toxicity" framing |
| Clinical Relevance | 8 | Directly informs treatment sequencing decisions for oncologists managing r/r FL today |
| Population Reach | 5 | Follicular lymphoma is moderately common (~20,000 new US cases/year); r/r subset is smaller |
| Implementation Speed | 7 | Retrospective real-world data; findings are immediately discussable in tumor boards |
| Evidence Strength | 6 | Multicenter; n=228; but retrospective and lacks randomization — selection bias is a major concern |
- Key quantitative result: CAR-T associated with longer PFS; greater healthcare contact burden in year 1 (exact HR/PFS not in abstract)
- External validation: Multicenter provides partial external validity; not prospectively validated
- Main limitation: Retrospective; patient selection bias between arms is not controlled; center-level variation in practice
- Equity implications: Both therapies are high-cost; time toxicity burden differentially affects patients with limited social support, transportation, or caregiver access — important equity dimension
- Evidence Maturity (confirmed): Validated ✓ (as real-world comparative; not practice-changing without prospective confirmation)
Article 5 — Zanubrutinib vs. Acalabrutinib in CLL/SLL (UC Academic Centers) | PMID 42961602
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Real-world BTK inhibitor comparison; adds to growing literature but not the first |
| Clinical Relevance | 7 | Directly relevant to prescribing choices in CLL/SLL; treatment persistence difference is clinically meaningful |
| Population Reach | 6 | CLL is the most common adult leukemia in Western countries (~20,000 new US cases/year) |
| Implementation Speed | 7 | Real-world data from academic centers; immediately informative for prescribing |
| Evidence Strength | 5 | Retrospective; n=481; single health system network; significant confounding potential |
- Key quantitative result: Zanubrutinib associated with longer treatment persistence; no significant difference in TTNT or OS (exact HR not available)
- External validation: None beyond the UC system; limited generalizability
- Main limitation: Retrospective with selection bias; no OS difference detected — may be underpowered
- Equity implications: Study from academic health centers — findings may not generalize to community oncology settings where most CLL is treated
- Evidence Maturity (confirmed): Validated ✓ (real-world evidence grade)
Article 6 — CGP Panel Selection in Biliary Tract Cancer | PMID 42961623
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Large-scale systematic comparison of tissue vs. liquid CGP panel yield in BTC; useful practical data |
| Clinical Relevance | 7 | Directly guides which panel to order for BTC patients seeking actionable mutations (e.g., FGFR2, IDH1) |
| Population Reach | 4 | Biliary tract cancer is relatively rare globally; highest incidence in Southeast Asia |
| Implementation Speed | 6 | Nationwide database; findings immediately applicable to panel ordering decisions |
| Evidence Strength | 6 | n=8,840 is large; database study limits; no outcome data linking panel choice to survival |
- Key quantitative result: Actionable alteration yield differed across panels (specific rates not in abstract)
- External validation: Nationwide database provides broad representativeness
- Main limitation: No outcome data; database study — coding accuracy unknown; abstract-only
- Equity implications: Access to CGP testing varies widely by geography and insurance status
- Evidence Maturity (confirmed): Validated ✓
Article 7 — Vertebral Fracture Hospitalization Trends in Germany | PMID 42961715
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Registry trend study; adds German 24-year data but concept is well-established |
| Clinical Relevance | 5 | Useful for health system planning; limited direct patient-care implications |
| Population Reach | 7 | Postmenopausal osteoporosis affects hundreds of millions globally |
| Implementation Speed | 6 | Policy-relevant; usable in health planning immediately |
| Evidence Strength | 6 | 24-year national registry; strong for trend analysis; abstract-only, no sample size given |
- Key quantitative result: Age-standardized rates stable/declining; absolute burden projected to remain high due to demographic aging
- Main limitation: Germany-specific; no intervention data; ecological design
- Equity implications: Older women, particularly those in lower socioeconomic strata, bear disproportionate fracture burden
- Evidence Maturity (confirmed): Validated ✓
Article 8 — Edentulism and Functional Disability in Older Adults | PMID 42961862
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Cross-national replication of known association; adds grip strength mediation pathway |
| Clinical Relevance | 5 | Supports oral health integration in geriatric care; not actionable without intervention data |
| Population Reach | 8 | n=63,074 across three continents; edentulism is globally prevalent in older adults |
| Implementation Speed | 5 | Observational; policy-relevant but requires intervention trials to change care |
| Evidence Strength | 6 | Large n; longitudinal and cross-national design; but observational with mediation analysis limitations |
- Key quantitative result: Consistent association between edentulism and disability across England, US, India; grip strength partial mediator
- Main limitation: Observational; causality unproven; cross-national comparability of measures uncertain
- Equity implications: Edentulism concentrated in low-income and underserved populations — findings have strong equity relevance
- Evidence Maturity (confirmed): Validated ✓
Article 9 — AI Detection of Pulmonary Embolism on V/Q Scintigraphy | PMID 42962362
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | AI for V/Q scintigraphy is less developed than CT-PA AI; novel application |
| Clinical Relevance | 6 | V/Q scans used in pregnancy and contrast-allergy patients; AI assist could reduce reader variability |
| Population Reach | 6 | PE is common; V/Q is a niche but important modality |
| Implementation Speed | 5 | Retrospective validation only; prospective trials needed before deployment |
| Evidence Strength | 6 | n=2,548 with holdout set; but retrospective; abstract-only |
- Key quantitative result: Best model matched human readers; low false-positive rate on low-pretest-probability holdout
- Main limitation: Retrospective; single-center implied; no clinical outcome data
- Equity implications: V/Q scanning is available in lower-resource settings where CT is unavailable — AI assist could improve diagnostic equity
- Evidence Maturity (confirmed): Validated ✓
Article 10 — ctDNA Monitoring for Metastatic Colorectal Cancer with Pulmonary Nodules | PMID 42962410
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | ctDNA-guided decision-making in a specific mCRC subgroup (small pulmonary nodules) is a focused and clinically relevant question |
| Clinical Relevance | 6 | Addresses real clinical dilemma; results are hypothesis-generating but directionally useful |
| Population Reach | 5 | Specific mCRC subgroup; moderately common clinical scenario |
| Implementation Speed | 4 | Prospective but small; exploratory; needs larger confirmatory trial |
| Evidence Strength | 5 | n=70 prospective; small but prospective design is a strength; exploratory by authors' own admission |
- Key quantitative result: Longitudinal ctDNA anticipated extrapulmonary progression; stratified progression risk (exact data not in abstract)
- Main limitation: n=70; single institution likely; exploratory designation appropriate
- Equity implications: ctDNA testing access is cost-limited in many health systems
- Evidence Maturity (revised): Exploratory ✓
Article 11 — Intralesional Cemiplimab for Early-Stage Cutaneous SCC | PMID 42962928
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Intralesional (vs. systemic) cemiplimab for early cSCC is a genuinely novel delivery approach |
| Clinical Relevance | 6 | Could reduce need for surgery in early-stage cSCC; relevant to dermatology practice |
| Population Reach | 6 | Cutaneous SCC is very common (hundreds of thousands annually in the US alone) |
| Implementation Speed | 4 | Phase 1/2; small cohort; needs larger randomized trial |
| Evidence Strength | 4 | Dose-escalation with expansion; uncontrolled; small n; no comparator arm |
- Key quantitative result: Antitumor activity with acceptable safety (exact response rates not in abstract)
- Main limitation: Small uncontrolled cohort; no comparator; very early
- Equity implications: Systemic PD-1 inhibitors are expensive; intralesional approach could theoretically reduce cost and systemic toxicity
- Evidence Maturity (confirmed): Exploratory ✓
Article 12 — Deep Learning for Middle Ear Disease Diagnosis | PMID 42963056
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | AI-assisted otoendoscopy diagnosis; well-explored concept in adjacent fields |
| Clinical Relevance | 6 | Improving diagnostic accuracy for less-experienced clinicians is directly relevant, especially in primary care settings |
| Population Reach | 6 | Ear disease is globally common; primary care physicians frequently see it without specialist support |
| Implementation Speed | 6 | Reader study design; relatively near to deployment if prospectively validated |
| Evidence Strength | 5 | Retrospective reader study; no sample size given in abstract; no prospective clinical outcomes |
- Key quantitative result: ~95% classification accuracy; improved performance for less-experienced readers
- Main limitation: Retrospective; no sample size provided; no clinical outcome data
- Equity implications: Most benefit in primary care / low-resource settings where ENT specialists are unavailable
- Evidence Maturity (confirmed): Validated ✓ (technical; clinical validation pending)
Article 13 — AAV Gene Therapy for Haemophilia A and B — Systematic Review | PMID 42963107
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Systematic review synthesizing existing knowledge; adds long-term safety signal surveillance value |
| Clinical Relevance | 7 | Hemophilia gene therapy is already in practice; durability/safety surveillance directly informs real-world use |
| Population Reach | 4 | Hemophilia A and B are rare (~400,000 affected worldwide); relative to unmet need, impact is significant |
| Implementation Speed | 7 | Products already approved; findings immediately relevant to patient monitoring |
| Evidence Strength | 6 | Systematic review design; limited by small individual trial sizes and product heterogeneity |
- Key quantitative result: Hemostatic benefit maintained in selected patients; durability and safety vary by product (specific data not in abstract)
- Main limitation: Pooled review of heterogeneous small trials; abstract-only; no meta-analysis data
- Equity implications: Gene therapy costs (~$2–3M/course) severely limit access globally; predominantly benefits high-income country patients
- Evidence Maturity (confirmed): Validated ✓
Article 14 — TAVI Long-Term Care Needs and Mortality in Japan | PMID 42963183
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Frailty-linked outcomes post-TAVI well studied; Japanese claims-linked data adds Asian-specific evidence |
| Clinical Relevance | 6 | Directly relevant to patient selection and pre-TAVI counseling |
| Population Reach | 6 | Aortic stenosis is common in older adults globally |
| Implementation Speed | 6 | Retrospective; findings immediately usable in clinical decision-making for TAVI candidate selection |
| Evidence Strength | 5 | n=1,361; retrospective claims; confounding by indication likely |
- Key quantitative result: Higher baseline care needs associated with >3× higher mortality post-TAVI
- Main limitation: Retrospective claims data; confounding; Japan-specific
- Equity implications: Frailty is more prevalent in lower-income and less-educated populations — these patients may be systematically under-referred for TAVI
- Evidence Maturity (confirmed): Validated ✓
Article 15 — INO-3107 DNA Immunotherapy for HPV-Associated RRP | PMID 42963203
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | DNA immunotherapy for RRP addresses a highly refractory condition with no approved systemic treatment; long-term T-cell data is novel |
| Clinical Relevance | 6 | Meaningful reduction in surgical procedures for a debilitating rare disease; but small uncontrolled study limits conclusions |
| Population Reach | 3 | RRP is rare (~2,000–4,000 US patients); but unmet need is severe and chronic |
| Implementation Speed | 4 | Phase 1/2 with extension; Phase 3 needed; 5+ years minimum |
| Evidence Strength | 4 | n=32; single-arm; no comparator; uncontrolled |
- Key quantitative result: Persistent HPV-specific T-cell responses; reduced surgical procedures over 2 years (specific rates not in abstract)
- Main limitation: Very small, uncontrolled; comparison to natural disease course is uncertain
- Equity implications: RRP has high burden in underserved populations; pediatric-onset particularly devastating
- Evidence Maturity (confirmed): Exploratory ✓
Article 16 — Childhood Hunger and Cognitive Impairment in China | PMID 42961077
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Adds to early-life adversity literature with TMLE methodology and Chinese cohort |
| Clinical Relevance | 4 | Observational; causality uncertain; no direct treatment implications |
| Population Reach | 8 | Childhood hunger affects billions globally; cognitive impairment in aging is a massive public health challenge |
| Implementation Speed | 4 | No intervention tested; policy implications are long-horizon |
| Evidence Strength | 5 | Nationwide case-control; TMLE is methodologically sophisticated; but retrospective recall of childhood hunger is subject to bias |
- Key quantitative result: Association between childhood hunger and cognitive impairment (effect size not in abstract)
- Main limitation: Retrospective recall bias; case-control design; causality not established
- Equity implications: Critical equity finding — early-life food insecurity shapes late-life health; most relevant to populations where food insecurity remains prevalent
- Evidence Maturity (confirmed): Validated ✓ (as association evidence)
Article 17 — Life Course Adversity and Intrinsic Capacity in Brazil | PMID 42961293
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Mediation analysis of life-course adversity in a Brazilian population; limited novel conceptual contribution |
| Clinical Relevance | 4 | Cross-sectional; education as intervention target is broad; no direct clinical intervention tested |
| Population Reach | 7 | Global relevance; particularly important for LMIC populations |
| Implementation Speed | 4 | Policy-level intervention; long time horizon |
| Evidence Strength | 4 | Cross-sectional limits causal inference; no sample size in abstract |
- Key quantitative result: Direct and indirect effects of childhood adversity on intrinsic capacity (specific effects not in abstract)
- Main limitation: Cross-sectional; mediation analysis cannot establish causation
- Equity implications: Strong equity relevance; Brazilian low-income populations most affected
- Evidence Maturity (confirmed): Validated ✓ (as observational association)
Article 18 — Cancer of Unknown Primary: Narrative Review | PMID 42961883
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative review; synthesizes evolving field but generates no new data |
| Clinical Relevance | 5 | Relevant to oncologists managing CUP; highlights treatment paradigm shift |
| Population Reach | 5 | CUP is ~2–5% of all cancer diagnoses; not rare |
| Implementation Speed | 4 | Narrative review; no new data to implement |
| Evidence Strength | 3 | Narrative review; inherently lower rigor |
- Evidence Maturity (confirmed): Validated ✓ (review-level synthesis)
Article 19 — External Validation and Implementation of Prediction Models — Systematic Review | PMID 42962244
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Meta-science finding; useful but not novel conceptually |
| Clinical Relevance | 5 | Directly relevant to AI/ML implementation science; informs journal editors and model developers |
| Population Reach | 5 | Broad relevance across all of clinical medicine |
| Implementation Speed | 5 | Findings directly actionable for researchers and journals (open code) |
| Evidence Strength | 6 | Systematic review; methodologically sound |
- Key quantitative result: Open code and stronger reporting associated with external validation; implementation driven by distinct factors
- Evidence Maturity (confirmed): Validated ✓
Article 20 — Plasma Metabolomics + ctDNA in DLBCL | PMID 42962272
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Combining plasma metabolomics with ctDNA for DLBCL risk stratification is genuinely novel |
| Clinical Relevance | 5 | Hypothesis-generating; would require validation in a prospective trial before clinical use |
| Population Reach | 6 | DLBCL is the most common aggressive lymphoma globally |
| Implementation Speed | 3 | Exploratory; metabolomics assay not standardized for clinical use |
| Evidence Strength | 5 | n=138 with independent validation cohort; exploratory design; abstract-only |
- Key quantitative result: Metabolite-based score improved risk stratification beyond ctDNA alone
- Evidence Maturity (confirmed): Exploratory ✓
Article 21 — SGLT2 Inhibitors: Genital/Urinary Infections by Sex and Indication | PMID 42962309
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Pharmacovigilance stratification by sex and indication adds nuance to known SGLT2 side-effect profile |
| Clinical Relevance | 6 | Directly informs counseling of women starting SGLT2 inhibitors |
| Population Reach | 8 | Tens of millions of patients globally on SGLT2 inhibitors |
| Implementation Speed | 7 | Immediately informative for prescriber counseling |
| Evidence Strength | 5 | Pharmacovigilance disproportionality analysis; reporting bias is inherent; no sample size given |
- Key quantitative result: Infection signal concentrated in women; driven by genital mycotic infections; stronger signal in diabetes than HF/CKD indications
- Evidence Maturity (confirmed): Validated ✓
Article 22 — Uncertainty-Aware Deep Learning for Adaptive Lung Radiotherapy | PMID 42962374
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Uncertainty quantification in adaptive radiotherapy image registration is a meaningful technical advance |
| Clinical Relevance | 5 | Technical innovation; clinical outcome benefit not yet demonstrated |
| Population Reach | 7 | Lung cancer is the leading cancer killer globally |
| Implementation Speed | 3 | Technical validation only; clinical integration requires prospective trial |
| Evidence Strength | 4 | Retrospective technical study; no sample size; no clinical outcomes |
- Evidence Maturity (confirmed): Exploratory ✓
Article 23 — SGLT2 Inhibitors in Rheumatic Diseases — Systematic Review | PMID 42962450
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Extends SGLT2 evidence into rheumatology; limited primary data |
| Clinical Relevance | 5 | Relevant to rheumatologists managing CV risk in autoimmune patients |
| Population Reach | 6 | SLE and SSc affect millions; CV risk is a leading cause of morbidity |
| Implementation Speed | 4 | Observational evidence base; no RCTs in this indication |
| Evidence Strength | 4 | Predominantly observational; limited disease-specific data |
- Evidence Maturity (confirmed): Exploratory ✓
Article 24 — Subgroup Calibration Audit for Perioperative Infection Prediction | PMID 42962674
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Subgroup calibration audit is methodologically important but not conceptually novel |
| Clinical Relevance | 5 | Directly relevant to AI model deployment safety; highlights frailty subgroup risk |
| Population Reach | 6 | Perioperative infection risk affects millions of surgical patients |
| Implementation Speed | 5 | Findings immediately relevant to model governance decisions |
| Evidence Strength | 5 | Retrospective audit; no sample size; abstract-only |
- Evidence Maturity (confirmed): Exploratory ✓
Article 25 — Cardiometabolic Abnormalities in Normal-Weight Adults | PMID 42962748
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | "Normal-weight obese" / metabolically unhealthy normal-weight phenotype is well-described |
| Clinical Relevance | 5 | Supports BMI-independent cardiometabolic risk screening |
| Population Reach | 8 | Globally relevant; large proportion of adults are normal-weight with metabolic risk |
| Implementation Speed | 5 | Cross-sectional; no intervention data; practice change requires more |
| Evidence Strength | 5 | Cross-sectional; no sample size in abstract; single country |
- Evidence Maturity (confirmed): Validated ✓
Article 26 — Multimodal Biosensing for Liquid Biopsy — Critical Review | PMID 42961770
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative review; useful synthesis but no new data |
| Clinical Relevance | 3 | Honest conclusion is that most platforms are pre-clinical; limited current clinical relevance |
| Population Reach | 7 | Cancer liquid biopsy broadly relevant |
| Implementation Speed | 2 | Review explicitly notes years away from clinical use |
| Evidence Strength | 3 | Critical narrative review; no systematic methods |
- Evidence Maturity (confirmed): Exploratory ✓
Article 27 — Peripheral Artery Disease in Hypertension — Narrative Review (Sentinel) | PMID 42961865
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Proposes structured case-finding approach; no new data |
| Clinical Relevance | 5 | PAD is underdiagnosed in hypertensive patients; case-finding framework has practical value |
| Population Reach | 8 | Hypertension affects ~1.3 billion people; PAD underdetection is global |
| Implementation Speed | 5 | Narrative proposal; no outcome trial to support it |
| Evidence Strength | 3 | Narrative review |
- Evidence Maturity (confirmed): Exploratory ✓
Article 28 — Sex-Specific Mechanisms in Heart Failure — Narrative Review | PMID 42961949
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Synthesis of sex-specific HF biology; growing literature area |
| Clinical Relevance | 5 | Conceptually important but narrative review generates no practice-changing evidence |
| Population Reach | 8 | Heart failure affects ~64 million globally |
| Implementation Speed | 3 | Review only; requires trial-level evidence to change care |
| Evidence Strength | 3 | Narrative review |
- Evidence Maturity (confirmed): Exploratory ✓
Article 29 — NETs-Related Gene Signature in Pancreatic Cancer | PMID 42962198
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | NETs-related prognostic signature in pancreatic cancer is a relatively novel angle |
| Clinical Relevance | 3 | Purely computational; prospective validation absent |
| Population Reach | 7 | Pancreatic cancer: ~500K deaths/year globally; detection unmet need is severe |
| Implementation Speed | 2 | Computational biomarker; needs extensive validation |
| Evidence Strength | 3 | Retrospective computational; no sample size; likely overfitting |
- Evidence Maturity (confirmed): Exploratory ✓
Article 30 — AI for Personalized Lung Cancer Diagnostics — Narrative Review | PMID 42962202
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Review of existing AI/lung cancer applications; well-trodden territory |
| Clinical Relevance | 3 | No new evidence; summarizes known landscape |
| Population Reach | 8 | Lung cancer is the leading cancer killer globally |
| Implementation Speed | 2 | Review only; individual applications have variable readiness |
| Evidence Strength | 2 | Narrative review |
- Evidence Maturity (confirmed): Exploratory ✓
Article 31 — SUMOylation Pathway Inhibition in AML | PMID 42962268
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | SUMOylation (TAK-981) as an AML therapeutic target is novel and mechanistically interesting |
| Clinical Relevance | 3 | Preclinical only; cannot exceed 5 per rules; mixed species |
| Population Reach | 6 | AML has poor prognosis; ~20,000 US cases/year |
| Implementation Speed | 2 | Preclinical; 5–10+ years minimum |
| Evidence Strength | 4 | Preclinical translational; patient-derived samples strengthen translational relevance but no human trial |
- Evidence Maturity (confirmed): Exploratory ✓
Article 32 — Incretin-Based Therapies in Psychiatry — Trial Registry Landscape | PMID 42962407
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Landscape analysis of a hot emerging area; useful orientation |
| Clinical Relevance | 4 | No completed positive trials; pipeline-level insight only |
| Population Reach | 8 | Addiction affects hundreds of millions; psychiatry broadly |
| Implementation Speed | 3 | No efficacy results yet in psychiatric indications |
| Evidence Strength | 4 | Registry analysis; inherent limitations |
- Evidence Maturity (confirmed): Exploratory ✓
Article 33 — MPN Single-Cell Omics Review | PMID 42962806
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Useful synthesis of single-cell omics in MPN; no new data |
| Clinical Relevance | 3 | Review of experimental science; no direct clinical implications yet |
| Population Reach | 5 | MPN is relatively rare |
| Implementation Speed | 2 | Laboratory science review |
| Evidence Strength | 3 | Narrative review |
- Evidence Maturity (confirmed): Exploratory ✓
Article 34 — CLDN18.2-Targeted CAR-NK Cells in Gastric Cancer | PMID 42962829
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | CAR-NK (vs. CAR-T) targeting CLDN18.2 in gastric cancer is a meaningful advance in a competitive space |
| Clinical Relevance | 3 | Preclinical only; cannot exceed 5 per rules |
| Population Reach | 7 | Gastric cancer is globally common, particularly in East Asia |
| Implementation Speed | 2 | Preclinical xenograft only |
| Evidence Strength | 3 | Preclinical; xenograft models have limited human translation predictability |
- Evidence Maturity (confirmed): Exploratory ✓
Article 35 — Nitisinone + Sorafenib for MSS-CRC | PMID 42963013
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Orphan drug repurposing (nitisinone) activating STING in immunotherapy-resistant CRC is conceptually creative |
| Clinical Relevance | 3 | Preclinical only; cannot exceed 5 per rules |
| Population Reach | 7 | MSS-CRC is the dominant CRC subtype and is immunotherapy-refractory — huge unmet need |
| Implementation Speed | 2 | Preclinical; clinical trials not yet reported |
| Evidence Strength | 3 | Preclinical multi-omic; no human data |
- Evidence Maturity (confirmed): Exploratory ✓
Article 36 — Cryofibrinogenemia Case Series | PMID 42961161
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Case series of a neglected rare disease; raises awareness but limited evidence generation |
| Clinical Relevance | 4 | Small but potentially practice-informing for a condition with no standard treatment |
| Population Reach | 2 | Ultra-rare disease |
| Implementation Speed | 4 | Clinical recognition immediately actionable; plasma exchange available |
| Evidence Strength | 2 | Case series; uncontrolled; classification_confidence = medium |
- Evidence Maturity (confirmed): Exploratory ✓
Article 37 — Mitochondrial DNA Abundance and Immunogenic Cell Death | PMID 42962666
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Published in Immunity; identifies mitochondrial DNA abundance as a functional determinant of immunogenic cell death — mechanistically significant |
| Clinical Relevance | 3 | Preclinical only; cannot exceed 5 per rules |
| Population Reach | 7 | Broad cancer relevance; particularly relevant to immunotherapy optimization |
| Implementation Speed | 2 | Preclinical mechanistic; 10+ years to clinical translation |
| Evidence Strength | 5 | Preclinical mechanistic; Immunity publication implies rigorous peer review; mixed species |
- Evidence Maturity (confirmed): Exploratory ✓